This 45-minute podcast features the expertise of a pathologist and an oncologist highlighting important and practice-changing developments related to the use of Ki67 biomarker testing in patients with HR-positive/HER2-negative early breast cancer, such as new clinical data with immediate implications for patient care. Case-based, and with expert perspectives and recommendations, this podcast addresses key educational gaps and controversies related to optimal Ki67 biomarker testing methods, including challenges with standardization, interpreting findings, and potential therapeutic implications for patients with HR-positive/HER2-negative early breast cancer to optimize clinical outcomes.Topics covered include:Analytical validity of Ki67 as a diagnostic assay, application of results in clinical practice, and relevance to therapyCurrent and emerging therapies for HR-positive/HER2-negative early-stage breast cancercurrent standardized methodologies for Ki67 quantificationOptimizing workflows and communications with the multidisciplinary teamThe activity offers 0.75 CME/CMLE credit.The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.Learning Objectives:Upon completion of this activity, you should be able to:Incorporate the evidence on the current use of Ki67 as a predictive and prognostic biomarker into clinical practiceEvaluate the clinical validity, utility, and differences among Ki67 assessment techniquesIntegrate best practices for Ki67 testing methodology, standardization, and reportingIdentify patients with high-risk features who may benefit from the addition of CDK4/6 inhibitor therapy to endocrine therapy in the adjuvant settingFoster collaborative discussions and workflows between oncologists, pathologists and the multidisciplinary team on recent clinical evidence to guide personalized treatment planning for HR-positive/HER2-negative early breast cancerIdentify patients with HR-positive/HER2-negative early breast cancer that expresses Ki67 who may be eligible for ongoing clinical trialsFaculty: Sunil S. Badve, MD, FRCPathVice Chair, Pathology Cancer Programs, Department of Pathology and Laboratory MedicineEmory University School of MedicineAtlanta, GA Manali Bhave, MDAssistant Professor, Department of Hematology and Medical OncologyEmory University School of MedicineAtlanta, GAThe American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.Credit Designation StatementThe ASCP designates this internet activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.ASCP designates this internet activity for a maximum of 0.75 CMLE credit. This activity meets CMP and state re-licensure requirements for laboratory personnel.For questions regarding CME credit, please contact ASCP Customer Service at 1-800-267-2727, during normal business hours: Monday through Friday, 8 a.m. to 6 p.m. Eastern TimeMethod of ParticipationTo complete the activity and receive credit, the participant must complete the online course. CME certificates will be provided online.Provided by the American Society for Clinical Pathology in partnership with Clinical Care Options, LLCThis activity is supported by an educational grant from Lilly.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related